Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Effects of ecstasy on cooperative behaviour and perception of trustworthiness: A naturalistic study

Journal of Psychopharmacology August 13, 2014 LH Stewart, Bart Ferguson, CJA Morgan et al. 28 citations

BACKGROUND: Acute recreational use of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') can promote pro-social effects which may alter interpersonal perceptions. AIMS: To explore such effects, this study investigated whether acute recreational use of ecstasy was associated with changes in individual perception of trustworthiness of people's faces and co-operative behaviours. METHOD: An...

The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.

Journal of Psychopharmacology August 1, 2014 Will Lawn, Monica J Barratt, Martin L Williams et al.

The NBOMe compounds are a novel series of hallucinogenic drugs that are potent agonists of the 5-HT2A receptor, have a short history of human consumption and are available to buy online, in most countries. In this study, we sought to investigate the patterns of use, characteristics of users and self-reported effects. A cross-sectional anonymous online survey exploring the patterns of drug use...

DOI: 10.1177/0269881114523866 (opens in new tab) Full text (opens in new tab) Demographics Nbome Hallucinogen Internet drug market +8

Differential effects of MDMA and methylphenidate on social cognition

Journal of Psychopharmacology July 22, 2014 Yasmin Schmid, Cédric M. Hysek, Linda D. Simmler et al. 154 citations

Social cognition is important in everyday-life social interactions. The social cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and methylphenidate (both used for neuroenhancement and as party drugs) are largely unknown. We investigated the acute effects of MDMA (75 mg), methylphenidate (40 mg) and placebo using the Facial Emotion Recognition Task, Multifaceted Empathy...

Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic

Journal of Psychopharmacology June 1, 2014 Peter R Diamond, Andrew D Farmery, Stephanie Atkinson et al.

Background: Ketamine has a rapid antidepressant effect in treatment-resistant depression (TRD). The effects on cognitive function of multiple ketamine infusions and of concurrent antidepressant medication on response rate and duration are not known. Method: Twenty-eight patients with uni- or bipolar TRD were treated over three weeks with either three or six ketamine infusions (0.5 mg/kg over 40...

Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling

Journal of Psychopharmacology April 30, 2014 Tobias Buchborn, H. Schröder, V. Höllt et al. 71 citations

A re-balance of postsynaptic serotonin (5-HT) receptor signalling, with an increase in 5-HT1A and a decrease in 5-HT2A signalling, is a final common pathway multiple antidepressants share. Given that the 5-HT1A/2A agonist lysergic acid diethylamide (LSD), when repeatedly applied, selectively downregulates 5-HT2A, but not 5-HT1A receptors, one might expect LSD to similarly re-balance the...

Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs).

Journal of Psychopharmacology March 27, 2014 Alfred Richard Green, David Nutt

Despite the publication of a substantial body of preclinical and clinical information on recent recreational drugs such as 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and cathinone compounds such as mephedrone there remains a disturbing lack of consensus as to how dangerous these compounds are to the health of the individual and to society in general. This perspective proposes that use...

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Journal of Psychopharmacology 2014 Peter S. Hendricks, Christopher Clark, Matthew W. Johnson et al. 88 citations

Hallucinogen-based interventions may benefit substance use populations, but contemporary data informing the impact of hallucinogens on addictive behavior are scarce. Given that many individuals in the criminal justice system engage in problematic patterns of substance use, hallucinogen treatments also may benefit criminal justice populations. However, the relationship between hallucinogen use...

DOI: 10.1177/0269881113513851 (opens in new tab) Addiction Hallucinogen Recidivism Abstinence +2

Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Journal of Psychopharmacology January 2014 John Turner, Andrew C. Parrott, Julia Goodwin et al.

The recreational drug MDMA (3,4-methylenedioxymethamphetamine) or 'Ecstasy' is associated with heightened psychiatric distress and feelings of depression. The Drugs and Infancy Study (DAISY) monitored the psychiatric symptom profiles of mothers who used Ecstasy/MDMA while pregnant, and followed them over the first year post-partum. We compared 28 young women whom took MDMA during their...

Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

Journal of Psychopharmacology November 27, 2013 Adam Winstock, Stephen J. Kaar, Rohan Borschmann 101 citations

This paper presents original research on prevalence, user characteristics and effect profile of N,N-dimethyltryptamine (DMT), a potent hallucinogenic which acts primarily through the serotonergic system. Data were obtained from the Global Drug Survey (an anonymous online survey of people, many of whom have used drugs) conducted between November and December 2012 with 22,289 responses. Lifetime...

Reviewing the ketamine model for schizophrenia

Journal of Psychopharmacology November 20, 2013 Joel Frohlich, John D Van Horn 310 citations

The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The glutamate hypothesis can explain negative and cognitive symptoms of schizophrenia better than the...

Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways

Journal of Psychopharmacology September 17, 2013 Aline Santos Monte, Greicy Coelho de Souza, Roger S McIntyre et al. 123 citations

It has been hypothesized that oxidative imbalance and alterations in nitrergic signaling play a role in the neurobiology of schizophrenia. Preliminary evidence suggests that adjunctive minocycline treatment is efficacious for cognitive and negative symptoms of schizophrenia. This study investigated the effects of minocycline in the prevention and reversal of ketamine-induced schizophrenia-like...

DOI: 10.1177/0269881113503506 (opens in new tab) Ketamine Minocycline Tbars Prepulse inhibition +6

Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

Journal of Psychopharmacology June 19, 2013 Rl Carhart-Harris, Stefan Brugger, Dj Nutt et al. 43 citations

Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the effects of five drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) in relation to psychiatric symptoms in a two-part subjective analysis. In the first part, mental health professionals...

Neural correlates of performance monitoring in chronic cannabis users and cannabis-naive controls.

Journal of Psychopharmacology June 2013 Daniel J Fridberg, Patrick D. Skosnik, William P Hetrick et al.

Chronic cannabis use is associated with residual negative effects on measures of executive functioning. However, little previous work has focused specifically on executive processes involved in performance monitoring in frequent cannabis users. The present study investigated event-related potential (ERP) correlates of performance monitoring in chronic cannabis users. The error-related...

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.

Journal of Psychopharmacology 2013 Michael C Mithoefer, Mark T Wagner, Ann T Mithoefer et al. 377 citations

We report follow-up data evaluating the long-term outcomes for the first completed trial of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for chronic, treatment-resistant post-traumatic stress disorder (PTSD) (Mithoefer et al., 2011). All of the 19 subjects who received MDMA-assisted treatment in the original trial participated in the long-term follow-up (LTFU), with 16 out of...

DOI: 10.1177/0269881112456611 (opens in new tab) Full text (opens in new tab) Psychedelic therapy MDMA-Assisted Psychotherapy MDMA Therapy Ecstasy therapy +18

A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)

Journal of Psychopharmacology October 31, 2012 Peter Oehen, Rafael Traber, Verena Widmer et al. 407 citations

Psychiatrists and psychotherapists in the US (1970s to 1985) and Switzerland (1988–1993) used MDMA legally as a prescription drug, to enhance the effectiveness of psychotherapy. Early reports suggest that it is useful in treating trauma-related disorders. Recently, the first completed pilot study of MDMA-assisted psychotherapy for PTSD yielded encouraging results. Designed to test the safety...

DOI: 10.1177/0269881112464827 (opens in new tab) MDMA Randomized controlled trial Placebo Adverse effect

Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell

Journal of Psychopharmacology October 17, 2012 Daniel I. Brierley, Colin Davidson 42 citations

Harmine is a β-carboline alkaloid and major component of ayahuasca, a traditional South American psychoactive tea with anecdotal efficacy for treatment of cocaine dependence. Harmine is an inhibitor of monoamine oxidase A (MAO-A) and interacts in vitro with several pharmacological targets which modulate dopamine (DA) neurotransmission. In vivo studies have demonstrated dopaminergic effects of...

DOI: 10.1177/0269881112463125 (opens in new tab) Ayahuasca Harmine Nucleus accumbens Pharmacology +3

Parallel changes in serotonin levels in brain and blood following acute administration of MDMA

Journal of Psychopharmacology October 10, 2012 Cheryl M Collins, Joris Kloek, J.m. Elliott 28 citations

Recent studies have demonstrated a similar acute effect of 3,4- methylenedioxymethamphetamine (MDMA) in blood platelets and brain tissue via action on the serotonin transporter. To investigate the validity of blood serotonin as a peripheral marker for central serotonin in this regard, we administered MDMA (20 mg/kg i.p.) to rats and observed a parallel decrease in serotonin levels in the...

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

Journal of Psychopharmacology October 5, 2012 Amir Englund, Paul D. Morrison, Judith Nottage et al. 463 citations

Community-based studies suggest that cannabis products that are high in Δ⁹-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment...

Δ⁹Tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques.

Journal of Psychopharmacology October 2012 Michael A. Taffe

Cannabis remains the most commonly abused illicit drug and is rapidly expanding in quasi-licit use in some jurisdictions under medical marijuana laws. Effects of the psychoactive constituent Δ⁹tetrahydrocannabinol (Δ⁹THC) on cognitive function remain of pressing concern. Prior studies in monkeys have not shown consistent evidence of memory-specific effects of Δ⁹THC on recognition tasks, and it...

4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.

Journal of Psychopharmacology July 1, 2012 Fernando Caudevilla-Gálligo, Jordi Riba, Mireia Ventura et al. 99 citations

4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive analogue of mescaline that is becoming increasingly popular as a rave and club drug. We investigated its presence in the illicit drug market in Spain, its pattern of use and profile of subjective effects. Drug material was analysed for 2C-B and information on pattern of use and subjective effects was obtained from recreational users....

DOI: 10.1177/0269881111431752 (opens in new tab) Full text (opens in new tab) 2c-b drug Synthetic drug 2c-b 2c-b substance Drug trends +18

Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images

Journal of Psychopharmacology May 13, 2012 Michael E. Ballard, Gillinder Bedi, Harriet de Wit 52 citations

There is growing evidence that drugs of abuse alter processing of emotional information in ways that could be attractive to users. Our recent report that Δ⁹-tetrahydrocannabinol (THC) diminishes amygdalar activation in response to threat-related faces suggests that THC may modify evaluation of emotionally-salient, particularly negative or threatening, stimuli. In this study, we examined the...

DOI: 10.1177/0269881112446530 (opens in new tab) Sadness Anger Happiness Affect linguistics +9

Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study.

Journal of Psychopharmacology May 2012 Matthew J Taylor, Eleanor R Tiangga, Roísín Ní Mhuircheartaigh et al.

Ketamine is a N-methyl-D-aspartic acid (NMDA) antagonist that has been associated with temporary clinical improvement in patients with depression. Studies using magnetic resonance spectroscopy (MRS) have shown that major depression is associated with decreased levels of glutamate and glutamine (Glx) in the anterior cingulate cortex, which normalize with clinical recovery. The present study...

Cannabinoid exposure in adolescent female rats induces transgenerational effects on morphine conditioned place preference in male offspring

Journal of Psychopharmacology April 19, 2012 J. Byrnes, Nicole L. Johnson, M. Schenk et al.

In the United States, marijuana is one of the drugs most abused by adolescents, with females representing a growing number of users. In previous studies, treatment of adolescent female rats with morphine significantly altered brain reward systems in future offspring. As both cannabinoid and opioid systems develop during adolescence, it was hypothesized that early exposure to cannabinoids would...

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Journal of Psychopharmacology March 8, 2012 Teri Suzanne Krebs, Pål-ørjan Johansen 580 citations

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse...

DOI: 10.1177/0269881112439253 (opens in new tab) Lysergic acid diethylamide Randomized controlled trial Context archaeology Meta-analysis +2

Effects of lamotrigine on PCP-evoked elevations in monoamine levels in the medial prefrontal cortex of freely moving rats.

Journal of Psychopharmacology December 1, 2011 Davide Quarta, Charles H Large

Lamotrigine is suggested to have potential as an add-on treatment for patients with schizophrenia. Supporting evidence comes from the efficacy of the drug in models of psychotic-like behaviour induced by N-methyl-D-aspartate (NMDA) receptor antagonists, such as phencyclidine (PCP). These drugs enhance levels of the monoamines in the cortex, which may contribute to their psychotomimetic effects....